Quick Answer
Werewolf Therapeutics, Inc. reported Stockholders Equity of $24.81 million for the year ending 2025.
- Werewolf Therapeutics, Inc. showed a decrease of -66.2% in Stockholders Equity from 2024 to 2025.
- This data is from Werewolf Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$28.07 million | Q2 2020: -$25.63 million | Q3 2020: -$31.56 million | Q1 2021: -$153.75 million | Q2 2021: $181.56 million | Q3 2021: $169.30 million | Q1 2022: $139.32 million | Q2 2022: $129.84 million | Q3 2022: $130.95 million | Q1 2023: $121.07 million | Q2 2023: $118.60 million | Q3 2023: $112.44 million | Q1 2024: $117.59 million | Q2 2024: $104.02 million | Q3 2024: $89.38 million | Q1 2025: $57.31 million | Q2 2025: $41.46 million | Q3 2025: $29.61 million.
- Over the full 7 years of available data (2019 to 2025), Werewolf Therapeutics, Inc.'s Stockholders Equity has grown by 202.1%.
- Historical annual values: Fiscal year 2025: $24.81 million | Fiscal year 2024: $73.39 million | Fiscal year 2023: $111.37 million | Fiscal year 2022: $122.34 million | Fiscal year 2021: $152.79 million | Fiscal year 2020: -$51.86 million | Fiscal year 2019: -$24.30 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: